OS Therapies Incorporated
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $73.3M
- Price
- $1.59
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.63%
- Volume
- 386.4K
About
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Quick stats
Shares outstanding46.1M
Computed float40.7M
Float / shares88.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001795091
Websitehttps://ostherapies.com
AI Summary
AI-generated1/43
standardbullishearnings
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
OS Therapies reported a Q2 net loss of $8.6 million, or $0.20 per share, compared to a loss of $4.8 million in the prior period. To fund operations into 2027, the company secured a $10 million debt facility backed by U.K. VAT refunds and R&D tax credits, with $5 million already funded.
Operationally, the company announced statistically significant 2.5-year overall survival data for OST-HER2 (75% vs 47%, p=0.003) and scheduled a Type C Statistical Methods Meeting with the FDA for mid-September. Management remains on track to submit a Biologics License Application (BLA) under the Accelerated Approval Program in the second half of 2026.
Regulatory progress included the MHRA waiving the Pediatric Investigation Plan requirement and the EMA granting Advanced Therapy Medicinal Product designation. The company also expects to receive over $4 million in R&D tax credits by the end of Q3 and appointed Dr. Craig Eagle to the Board of Directors.
Red flags
- Operating loss comparison period mismatched in text (Q2 2026 vs Q1 2025)
- Weighted average shares outstanding increased significantly YoY to 43.9M from 25.1M